TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Ribomic, Inc. ( (JP:4591) ) has issued an update.
RIBOMIC, Inc. announced the discovery of therapeutic effects of umedaptanib pegol in a diabetic retinopathy model and has filed a patent for its use in treating this condition. Diabetic retinopathy is a major complication of diabetes and a leading cause of blindness. The promising results from the study suggest that umedaptanib pegol could offer a new treatment option, potentially enhancing RIBOMIC’s clinical pipeline and corporate value.
More about Ribomic, Inc.
RIBOMIC, Inc. is a clinical-stage biopharmaceutical company that focuses on the discovery and development of aptamer therapeutics, a type of nucleic acid medicine. The company utilizes its RiboART system to develop drugs targeting unmet medical needs, including eye diseases and rare childhood diseases.
Average Trading Volume: 2,439,598
Technical Sentiment Signal: Sell
Current Market Cap: Yen4.85B
Learn more about 4591 stock on TipRanks’ Stock Analysis page.